Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
Actuate Therapeutics IncNASDAQ: ACTU
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock rises 20.0% from a year ago
Common stock stood at $24 at the end of Q1 FY2026, up 20.0% from a year earlier and up 4.3% from the prior quarter. Over 3 fiscal years it compounded at +97.2% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether common stock keeps rising in the next quarterly balance sheet after a +20.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 23 USD
- Year-over-year change
- +15.0%
- 3-year CAGR
- +97.2%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23 | +15.0% |
| FY2024 | 2024-12-31 | 20 | +900.0% |
| FY2023 | 2023-12-31 | 2 | -33.3% |
| FY2022 | 2022-12-31 | 3 | — |
Common Stock vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +20.0% is the 4th highest of 9, against a peer median of +13.7%.
- Common stock amounts to 0.0% of total assets for ACTU, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CHF 4.02M CHF | -0.3% | +3.9% | 4.6% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $186K USD | +16.3% | +290.0% | 0.8% |
| Mar 2026 | $58K USD | +3.6% | +2.5% | 0.1% | |
| Mar 2026 | $19K USD | +46.2% | +37.0% | 0.0% | |
| Mar 2026 | $11K USD | +22.2% | +11.2% | 0.0% | |
| Mar 2026 | $10K USD | +11.1% | -56.9% | 0.0% | |
| Mar 2026 | $7K USD | +0.0% | +11.9% | 0.0% | |
| Mar 2026 | $7K USD | +133.3% | +51.8% | 0.0% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $24 USD | +20.0% | +97.2% | 0.0% |
| Peer median (excluding ACTU) | — | +13.7% | +11.5% | 0.0% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.